It's a flop: Gilead­'s top late-stage drug selon­sert­ib flunked its first Phase III NASH tri­al

Gilead’s high pro­file STEL­LAR-4 study of its top late-stage NASH drug selon­sert­ib has hit the fin­ish line, and it’s start­ing out Phase III re­sults with a big-time fail­ure.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.